PCSK9 inhibitors: Emerging treatment to lower cholesterol?;Inhibiteurs de PCSK9: Futur traitement pour baisser le cholestérol?

Revue Medicale Suisse

Volumn 10, Issue 420, 2014, Pages 539-544

  Gencer, B ^a   Rodondi, N ^b   Mach, F ^a  

^a Service de Cardiologie   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; EVOLOCUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PLACEBO;

CARDIOVASCULAR DISEASE; CLINICAL STUDY; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; LOSS OF FUNCTION MUTATION; OBSERVATIONAL STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84898631007     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
2. Perk J, De Backer G, Gohlke H. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701.
3. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458-73.
4. * Martin SS, Gosch K, Kulkarni KR, et al. Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. Am Heart J 2013;165:26-33, e23.
5. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Therapeut 2013;35:1082-98.
6. Davidson MH. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. J Clin Lipidol 2013;7:S11-5.
7. Farnier M. PCSK9 inhibitors. Curr Opin Lipidol 2013;24:251-8.
8. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low ldl cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37:161-5.
9. ** Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. New Engl J Med 2012;367:1891-900.
10. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, sar236553/regn727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59:2344-53.
11. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, regn727/sar236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet 2012;380:29-36.
12. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. New Engl J Med 2012;366:1108-18.
13. Sullivan D, Olsson AG, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The gauss randomized trial. JAMA 2012;308:2497-506.
14. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: Results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012;60:1888-98.
15. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (laplace-timi 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012;380:2007-17.
16. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (rutherford) randomized trial. Circulation 2012;126:2408-17.
17. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New Engl J Med 2006;354:1264-72.
18. Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res 2008;49:1595-9.
19. Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 2013;228:18-28.
20. * Vogel RA. PCSK9 inhibition: The next statin? J Am Coll Cardiol 2012;59:2354-5.